LynxCare's comprehensive data asset* offers fresh insights into patients treated with Immune Checkpoint Inhibitors including comorbidity factors, treatment patterns, adverse events (cardiotoxicity) and median overall survival. With over 2000 estimated patients and 579 endpoints measured, our granular and quality-controlled real-world dataset can unlock invaluable insights into the treatment and prognosis of immuno-oncology (IO), empowering clinicians to make informed decisions.
Closing the Gap
The Value of Unstructured Data in Immuno-Oncology
Comorbidity Data Gap
The majority of randomized clinical trials for immuno-oncology exclude patients with significant comorbidities, yet these patients make up a large proportion of the immuno-oncology population.
Our data asset offers insights into the relationship of specific comorbidities, adverse events and biomarkers with immuno-oncology prognosis, bridging an important knowledge gap and informing treatment and follow-up decisions.
Evidenced by our data which yielded a higher prevalence of Dementia of 10% compared to 5% with structured data alone.
Reason for treatment line switch
Structured data alone only provides part of the picture, missing key nuances. Combining structured data with rich EHR narrative data can improve our understanding of toxicity reasons, as evidenced by our data which yielded a higher auto-immune disease detection of 13.5 % compared to 4.7 % with structured data alone.
Using our real-world dataset, with a mean follow-up time of over four years, we can analyze adverse events, OS, and treatment patterns in real time, providing invaluable insights into the patient pathway of immuno-oncology.
Unpacking the Data
The Sources Behind Our Insights
- Patient demographics
- Vital signs
- Claims data
- Tumor staging
- Active and inactive medical problems
- Surgical interventions
- Hospital procedures, visits & hospitalizations
- In and out of hospital mortality
- Drug regimens
- Doses and durations of chemotherapy, radiation, immunotherapy
- Immuno-Modulary treatments
- Gene expression profiles
- Molecular-level information
Diversity and Real-World Representation in Our Dataset
Our dataset reflects the diversity of the Belgian population, which includes a mix of different nationalities. For example, in Brussels alone there are 189 different nationalities and 40% of the population is not native. In addition, the LynxCare datasets continue to expand, encompassing real-world data from hospitals across Europe.
We also try to maintain a 50/50 split of academic vs non-academic settings per project to ensure that our data reflects the real world. At LynxCare, we believe that real-world data should be just that - real.
Immuno-Oncology Dataset Insights
Our dataset* provides valuable insights into immuno-oncology, including but not limited to:
Quality Control and Data Freshness
We adhere to strict data quality standards to ensure the accuracy and reliability of our data. Our team of experts verifies and validates data from intake, data processing up till analytics, ensuring consistency and completeness throughout the patient pathway. Each statistic needs to be validated by the individual hospital before delivery.
Our data is updated regularly to ensure we provide insights based on the latest and most accurate information. Leveraging our HL7-based gateway, our datasets remain fresh with a max of 6-months delay.
OMOP CDM Data Warehouse
Our data is stored in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), enabling easy access and integration with other healthcare or research IT solutions. With our well-structured and standardized data storage, our clients can start analyzing the data immediately and efficiently.
More Than Just Numbers
Our data asset goes beyond just providing numbers and statistics. It offers insights into the individual pathways of immuno-oncology patients, enabling clinicians to tailor treatments to the specific needs of each patient.
Our data asset has been used by healthcare providers as well as clinical researchers, enabling cross-disciplinary collaboration and innovation in immuno-oncology treatment and management, leading to insights useful to compare OS in the real-world vs phase III trials in different treatment line settings.
Impact on Patient Outcomes
Ultimately, our data asset aims to improve the lives of immuno-oncology patients by providing insights that lead to better clinical outcomes and patient experiences. With our comprehensive dataset, clinicians and researchers can tailor treatments to the real-world patient population, ultimately leading to better outcomes.
How Pharma Can Leverage LynxCare's Dataset
Pharmaceutical companies leverage LynxCare's comprehensive EU dataset to gain insights and develop new treatments.
Our data is particularly useful for:
Unlock Research Questions
Insights for Life Science Companies
Our dataset offers life science companies unparalleled insights into the relationship between specific biomarkers, comorbidities, and treatment outcomes in immuno-oncology.
|Incidence & Prevalence
|Hospital visit &
The LynxCare Advantage
We do our best to ensure representativity by including data from a mix of academic and non-academic centers. This captures the real-world patient and treatment pathway.
Our team of data experts has a combined 50+ years of experience in healthcare data analytics and quality control.
We partner with clinical experts in IO and other specialties to ensure our data offers relevant and valuable insights for healthcare professionals.
Hospital Network & Data Access
The hospitals remain in control over their own data. Each RWE request is individually handled following data governance guidelines and timelines in
our master service agreement to accelerate the delivery of insights.
Partnership with the best statistical firms
LynxCare partners with statistical firms who already have a working relationship with the life science company.
Differentiating factors from other NLP providers & established RWD vendors
The Future of Immuno-Oncology Treatment
How LynxCare Can Help
By providing insights into individual pathways of immuno-oncology patients, our data asset enables
clinicians to tailor treatments to specific patient needs, opening up the possibility of personalized medicine for immuno-oncology.
By providing insights into the clinical pathway of immuno-oncology patients, our data asset aims to ultimately improve patient outcomes by providing valuable insights for clinicians and researchers.
With our comprehensive dataset and world-class expertise, we aim to continue to drive innovation in immuno-oncology treatment and management, ensuring that the latest insights and solutions are available to healthcare providers and researchers.
*LynxCare datasets concern datasets within the LynxCare's European hospital network. The hospitals are the data controllers. No commitment before site approval on RWE request.